Stock HLVX HILLEVAX, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages HilleVax, Inc.

Equities

HLVX

US43157M1027

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-05 pm EDT 		5-day change 1st Jan Change
13.77 USD +0.36% Intraday chart for HilleVax, Inc. +8.94% -14.21%
May. 24 Recursion Names HilleVax CEO Robert Hershberg as New Board Chair MT
May. 22 Hillevax Insider Sold Shares Worth $266,291, According to a Recent SEC Filing MT

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Recursion Names HilleVax CEO Robert Hershberg as New Board Chair
Hillevax Insider Sold Shares Worth $266,291, According to a Recent SEC Filing
HilleVax, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Hillevax Insider Sold Shares Worth $264,467, According to a Recent SEC Filing
HilleVax Insider Sold Shares Worth $985,536,428, According to a Recent SEC Filing
HilleVax Proposes $500 Million Offering of Equity, Debt Securities in Shelf Registration
HilleVax Q4 Net Loss Widens; Shares Extend Decline After Hours
HilleVax, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
HilleVax, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
HilleVax Names New Chief Operating Officer
HilleVax, Inc. Announces Executive Changes
Hillevax Insider Sold Shares Worth $287,000, According to a Recent SEC Filing
Hillevax Insider Sold Shares Worth $140,000, According to a Recent SEC Filing
HilleVax Q3 Net Loss Widens
HilleVax, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
HilleVax Prices $100 Million Common Stock Offering
HilleVax, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
HilleVax, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
HilleVax, Inc. Appoints Nanette Cocero as Board of Director
HilleVax Announces Completion of Enrollment of NEST-IN1 Phase 2b Clinical Study of HIL-214 Norovirus Vaccine Candidate
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. HLVX Stock
  4. News HilleVax, Inc.
  5. Other languages